Biogen Inc
NASDAQ:BIIB

Watchlist Manager
Biogen Inc Logo
Biogen Inc
NASDAQ:BIIB
Watchlist
Price: 180.44 USD -0.47% Market Closed
Market Cap: 26.5B USD

BIIB's latest stock split occurred on Jan 18, 2001

The company executed a 3-for-1 stock split, meaning that for every share held, investors received 3 new shares.

The adjusted shares began trading on Jan 18, 2001. This was BIIB's 2nd stock split, following the previous one in Dec 21, 1999.

Last Splits:
Jan 18, 2001
3-for-1
Dec 21, 1999
2-for-1
Pre-Split Price
N/A
Post-Split Price
37.49
Before
After
Last Splits:
Jan 18, 2001
3-for-1
Dec 21, 1999
2-for-1

Biogen Inc
Stock Splits History

BIIB Stock Splits Timeline
Jan 18, 2001
Jan 18, 2001
Split 3-for-1
x3
Pre-Split Price
N/A
Post-Split Price
37.49
Before
After
Dec 21, 1999
Dec 21, 1999
Split 2-for-1
x2
Pre-Split Price
N/A
Post-Split Price
37.49
Before
After

Global
Stock Splits Monitor

Date Company Split Pre-Split Price Post-Split Price
Dec 29, 2025
Ise Chemicals Corp
OTC:ICHMF
10-for-1
x10
32.808 32.808 USD N/A
Dec 29, 2025
Bridgestone Corp
OTC:BRDCF
2-for-1
x2
45.17 45.17 USD N/A
Dec 29, 2025
Ibiden Co Ltd
OTC:IBIDF
2-for-1
x2
81 81 USD N/A
Dec 29, 2025
Itochu Corp
OTC:ITOCF
5-for-1
x5
59.434 59.434 USD N/A
Dec 29, 2025
Sumitomo Realty & Development Co Ltd
OTC:SURDF
2-for-1
x2
47.945 47.945 USD N/A
Load More

Biogen Inc
Glance View

Biogen Inc. finds its roots in the cutting-edge world of biotechnology, where science meets the needs of patients battling complex neurological diseases. Founded in 1978 by a group of visionary scientists, including Nobel laureates, Biogen has evolved into a leader known primarily for its focus on neuroscience. Nestled in Cambridge, Massachusetts, the company operates with a singular goal—transforming the understanding and treatment of neurological disorders. The enterprise drives its mission through rigorous research and development (R&D), which forms the backbone of its operations. Biogen invests substantial resources in unveiling the mysteries of diseases such as multiple sclerosis (MS), Alzheimer's, and spinal muscular atrophy, striving to pioneer therapies that can profoundly improve patient outcomes. Biogen's revenue model is heavily contingent upon the successful commercialization of its R&D endeavors. The company primarily earns its revenue by developing and marketing prescription drugs that target neurological conditions. Signature products, such as Tecfidera, Tysabri, and Spinraza, have become mainstays in the management of multiple sclerosis and spinal muscular atrophy, respectively, delivering significant returns. By continually reinvesting in its drug pipeline, Biogen stays at the forefront of biopharmaceutical innovation, seeking to expand its portfolio and rigging favorable licensing deals and collaborations along the way. These elements ensure not just the sustenance but also the growth of its market presence, driving the company forward in a competitive and ever-evolving industry landscape.

BIIB Intrinsic Value
HIDDEN
Show
Back to Top